(Q34807240)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12206877%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

review article

1 reference

title

Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12206877%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12206877%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Tomos Walters

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12206877%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

author name string

Stephen Locarnini

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12206877%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 September 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12206877%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12206877%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12206877%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12206877%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

381-396

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12206877%20AND%20SRC:MED&resulttype=core&format=json

9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo

12 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Detection of hepatitis B virus DNA in hepatocytes, bile duct epithelium, and vascular elements by in situ hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Virus dynamics and drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Affinity of antibody responses in man to hepatitis B vaccine determined with synthetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Hepatitis B virus immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Cytotoxic T cells and viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

The carbocyclic analog of 2'-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Viral antigen expression in the pancreas of DHBV-infected embryos and young ducks

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Real time quantitative PCR

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

cis-acting sequences required for encapsidation of duck hepatitis B virus pregenomic RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

New therapies for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Hepatitis B surface antigen assembles in a post-ER, pre-Golgi compartment

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: an experimental study in the chimpanzee

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

A study of the pharmacokinetic interaction between lamivudine and alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Duck hepatitis B virus replication in primary bile duct epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Coordinate regulation of replication and virus assembly by the large envelope protein of an avian hepadnavirus.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Hepatitis B virus DNA in liver and white blood cells of patients with hepatoma

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

How can the cellular immune response control hepatitis B virus replication?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Strategies to prevent and control hepatitis B and C virus infections: a global perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Hepatitis B virus replication--an update

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Demonstration of duck hepatitis B virus in bile duct epithelial cells: implications for pathogenesis and persistent infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Decay characteristics of HIV-1-infected compartments during combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Cytotoxic T-cell responses to the nucleocapsid proteins of HBV in chronic hepatitis. Evidence that antibody modulation may cause protracted infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Pharmacogenetics and psychopharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Infection of bone marrow cells by hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Hepatitis B virus biology

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Combination chemotherapy for hepatitis B virus: the final solution?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Preclinical aspects of lamivudine and famciclovir against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Secreted hepatitis B surface antigen polypeptides are derived from a transmembrane precursor

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Update: genetic polymorphism of drug metabolizing enzymes in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Evidence for activation of the hepatitis B virus polymerase by binding of its RNA template.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Duck hepatitis B virus infection of non-hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Kinetics of acute hepatitis B virus infection in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Dynamics of hepatitis B virus infection in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900071-2

7 January 2021

10.1016/S0166-3542(02)00071-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12206877%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference